Pharmaceutical IP Experts Opine on Royalty Payments for Drug Patent Holder

Case Overview

The case involves a licensing dispute centered in the state of Georgia involving the formulation and testing of a drug that treats neurologic conditions. The drug is a combination of two existing medications, which have been combined into a single therapy. The patent holder and manufacturer of these existing medications claimed that they should receive a greater amount of royalty payments for the new drug. The manufacturer of the new therapy has claimed that the royalty and licensing payments made to the original inventor of the component drugs are sufficient.